Bluebird Bio company information, Employees & Contact Information

bluebird bio Announces Completion of Acquisition by Carlyle and SK Capital Business Wire

Important Information for bluebird bio Stockholders to Tender Shares for Acquisition by Carlyle and SK Capital Yahoo Finance

Can bluebird bio Hit $600M Sales Target? What the $9.84 Per Share Buyout Really Means Stock Titan

Carlyle, SK Capital Partners and bluebird bio Amend Merger Agreement Business Wire

Carlyle, SK Capital Partners and bluebird bio Provide Updated Tender Instructions Yahoo Finance

bluebird bio Reminds Stockholders to Act Now to Tender Shares for Acquisition by Carlyle and SK Capital Business Wire

FDA Approves bluebird bio's Lovo-Cel Gene Therapy for Sickle Cell Disease CGTLive®

bluebird bio Announces Completion of Acquisition by Carlyle and SK Capital citybiz

Hematological Malignancies Detected in Some Patients Treated With bluebird bio’s Active Cerebral Adrenoleukodystrophy Gene Therapy Eli-Cel CGTLive®

bluebird bio Announces 1-for-20 Reverse Stock Split Yahoo Finance

bluebird bio Reports Third Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance Yahoo Finance

bluebird bio Adjourns Meeting of Stockholders and Announces Third Quarter Results Call Yahoo Finance

Carlyle and SK Capital Receive All Required Regulatory Approvals to Complete the Acquisition of bluebird bio Yahoo Finance

bluebird bio Presents Positive Long-Term Data On LYFGENIA™ (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and Exposition Yahoo Finance

bluebird bio Confirms Participation in Center for Medicare and Medicaid Innovation (CMMI) Cell and Gene Therapy Access Model Yahoo Finance

Tami John, MD, on Barriers to Access for Gene Therapy in β-Thalassemia CGTLive®

Bristol Myers Squibb and bluebird bio Provide Regulatory Update on Idecabtagene Vicleucel (ide-cel, bb2121) for the Treatment of Patients with Multiple Myeloma Bristol Myers Squibb

Acute Myeloid Leukemia Case after Gene Therapy for Sickle Cell Disease The New England Journal of Medicine

bluebird bio’s Transfusion-Dependent β-Thalassemia Gene Therapy Beti-Cel Continues to Demonstrate Curative Potential in Long-Term Follow-Up Data CGTLive®

Bluebird Bio and Resilience Announce Strategic Alliance to Develop Next Generation Cell Therapies Business Wire

bluebird bio Chief Strategy and Financial Officer Jason Cole to Retire citybiz

bluebird bio Announces Completion of its Q2 2024 Form 10-Q Filing FinancialContent

Earnings call: Bluebird bio sees patient growth, aims for 2025 breakeven Investing.com

bluebird bio Appoints Joseph Vittiglio, JD, as Chief Business and Legal Officer citybiz

Carlyle's bluebird Deep Discount Buyout (Rating Upgrade) Seeking Alpha

U.S. Food and Drug Administration Approves Bristol Myers Squibb’s and bluebird bio’s Abecma (idecabtagene vicleucel), the First Anti-BCMA CAR T Cell Therapy for Relapsed or Refractory Multiple Myeloma Bristol Myers Squibb

bluebird bio Announces First Quarter 2023 Earnings Date and Upcoming Investor Events FinancialContent

Bristol Myers Squibb and bluebird bio Announce Submission of Biologics License Application (BLA) to FDA for Idecabtagene Vicleucel (Ide-cel, bb2121) for Adults with Relapsed and Refractory Multiple Myeloma Bristol Myers Squibb

Heterogeneity of the long-term economic burden of severe sickle cell disease: a 5-year longitudinal analysis Taylor & Francis Online

Recoding for Life: An Interview with One of Gene Therapy's High Fliers: Mary Ann Liebert, Inc.

bluebird bio Announces Key Management and Board Appointments citybiz

Clinical Overview: Skysona for Early Cerebral Adrenoleukodystrophy Pharmacy Times

FDA approves SKYSONA for boys aged 4 to 17 years Contemporary Pediatrics

Clinical Trial Data Support Safety, Efficacy of Lenti-D for Boys with CALD Adrenoleukodystrophy News

The top 10 takeover targets in biopharma Fierce Biotech

bluebird bio Announces Completion of its Restatement and filing of its 2023 Form 10-K and Q1 2024 Form 10-Q FinancialContent

bluebird bio : Presents New Results from Clinical Development Program of elivaldogene autotemcel (eli-cel, Lenti-D™) Gene Therapy for Cerebral Adrenoleukodystrophy (CALD), Including Updated Long-Term Data, at the 46th Annual Meeting of the EBMT MarketScreener